Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS • Currently down 0.92 (-3.95%) in today's trading session

1 member of Congress has disclosed 2 trades in Arcutis Biotherapeutics, Inc. (ARQT) via STOCK Act filings. The most recent disclosure was a purchase by Josh Gottheimer on 17 April 2023. Aggregate disclosed activity totals roughly $16K in purchases (midpoint estimates from bracketed disclosure amounts).

Arcutis Biotherapeutics, Inc. is currently trading at $22.37, positioned at 51% of its 52-week range ($12.42 – $31.77).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$22.37
24h Change
-0.92 (-3.95%)
52 Week Range
$12.42—$31.77
View on NASDAQ

Arcutis Biotherapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ARQT

Select to highlight on chart
2 transactions
Compliance: 100%
Josh Gottheimer17 Apr 202319 May 2023PurchaseStock$1,001 - $15,000N/A
Josh Gottheimer15 Jun 202222 Jul 2022PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.77B

Volume

1.11M

Beta

1.77

P/E Ratio

-172.08

Fundamentals

EPS

$-0.13

Div. Yield

—

Open

$22.86

Day Range

$22.13 — $23.14

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Todd Franklin Watanabe
IPO Date
2020-01-31
Website
www.arcutis.com

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical tri...

Earnings

Next Report

Q1 2026

6 May

EPS Est.

$-0.02

Rev. Est.

$103.7M

Days Until

7

Recent Quarters

Q4 202525 Feb
EPS$0.13
Beat 333.3%
Q3 202528 Oct
EPS$0.06
Beat 160.0%
Q2 20256 Aug
EPS$-0.13
Beat 27.8%
Q1 20256 May
EPS$-0.20
Beat 4.8%
Q4 202425 Feb
EPS$-0.09
Beat 67.9%
Q3 20246 Nov
EPS$-0.33
Beat 21.4%
Q2 202414 Aug
EPS$-0.42
Beat 12.5%
Q1 202414 May
EPS$-0.32
Beat 46.7%
Q4 202327 Feb
EPS$-0.72
Miss 10.8%
Q3 20233 Nov
EPS$-0.73
Beat 18.9%
Q2 20238 Aug
EPS$-1.16
Beat 4.9%
Q1 20239 May
EPS$-1.31
Miss 0.8%
Q4 202228 Feb
EPS$-1.18
Beat 13.9%
Q3 20228 Nov
EPS$-1.89
Miss 22.7%
Q2 20224 Aug
EPS$-1.31
Beat 5.1%
Q1 20225 May
EPS$-1.27
Beat 10.6%
Q4 202122 Feb
EPS$-1.42
Miss 0.7%
Q3 20214 Nov
EPS$-1.14
Miss 4.6%
Q2 20215 Aug
EPS$-0.84
Beat 7.7%
Q1 20214 May
EPS$-0.76
Beat 20.8%
Q4 202016 Feb
EPS$-0.79
Beat 11.2%
Q3 20205 Nov
EPS$-1.01
Miss 6.3%
Q2 202011 Aug
EPS$-0.94
Miss 11.9%
Q1 202012 May
EPS$-1.15
Miss 25.0%
Q4 201919 Mar
EPS$-6.18
Beat 32.9%
Q4 201931 Jan
EPS$-0.40
Q1 201930 Jun
EPS$-0.22
Q4 201831 Mar
EPS$-0.17
Q3 201831 Dec
EPS$-0.15
Q2 201830 Sept
EPS$-0.21
Q1 201830 Jun
EPS$-0.08
Q4 201731 Mar
EPS$-0.08

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

NVDA

NVIDIA Corporation

20
$209.25-3.82 (-1.79%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

PTSNX

PIMCO Short Term I-3

17
$9.680.00 (0.00%)
Held by same politician
1 politician
View Stock

NFLX

Netflix, Inc.

17
$92.12-0.17 (-0.19%)
Communication Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about ARQT

Which members of Congress have traded ARQT?
1 member of Congress has disclosed 2 trade in Arcutis Biotherapeutics, Inc. (ARQT) under the STOCK Act: Josh Gottheimer.
When was ARQT most recently disclosed by Congress?
The most recent ARQT disclosure was a purchase by Josh Gottheimer on 17 April 2023.
What is the total disclosed congressional trading volume for ARQT?
Members of Congress have disclosed approximately $16K in ARQT purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in ARQT?
This ARQT page updates as soon as new STOCK Act disclosures are filed for Arcutis Biotherapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.